2. Immunology/Inflammation
  3. Complement System
  4. Eculizumab

Eculizumab  (Synonyms: Anti-Human C5, Humanized Antibody; h5G1.1)

Cat. No.: HY-P9914 Purity: 99.88%
COA
SDS
Technical Support

Eculizumab (Anti-Human C5, Humanized Antibody) is a long-acting humanized monoclonal antibody targeted against complement C5. Eculizumab inhibits the cleavage of C5 into C5a and C5b and inhibits deployment of the terminal complement system including the formation of membrane attack complex (MAC). Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in mice. Eculizumab can be used in hemolysis studies.

For research use only. We do not sell to patients.

CAS No. : 219685-50-4

Size Price Stock Quantity
Free Sample (100 μg)   Apply Now  
1 mg In-stock
5 mg In-stock
10 mg In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 4 publication(s) in Google Scholar

Eculizumab Featured Recommendations:

Eculizumab Related Antibodies

Top Publications Citing Use of Products

    Eculizumab purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2025 Nov 5;10(1):362.  [Abstract]

    Cyclic peptide Cp1, Cp3 or anti-C5 antibody (Eculizumab)-induced erythrocyte hemolysis rate quantified by hemoglobin absorbance at 540 nm, n = 3.

    Eculizumab purchased from MedChemExpress. Usage Cited in: Cell. 2025 May 29;188(11):3013-3029.e19.  [Abstract]

    The quantification of free Hb from human RBCs as indicated in vitro (n = 4). The results showed that the administration of Eculizumab (50 mg/mL; 30 min) significantly hampered the release of free Hb induced by activated complement compared with that of controls.

    Eculizumab purchased from MedChemExpress. Usage Cited in: Sci Rep. 2025 Dec 8;15(1):43346.  [Abstract]

    LDH assay results with cell lysis normalized to lysis buffer-treated cells and additional AC/IC-only background absorbance subtraction. Effects of Eculizumab on U-87MG-AQP4-ECFP cells after complement and E5415A treatment. Cells were treated with active or heat-inactivated human complement (AC/IC) in combination with E5415A (10 µg/mL). In addition to E5415A + AC, complement inhibitors against C5 (Eculizumab, 30 µg/mL) were added to the complement 15 min before the application on cells.

    Eculizumab purchased from MedChemExpress. Usage Cited in: Sci Rep. 2025 Dec 8;15(1):43346.  [Abstract]

    qPCR results of genes differently expressed in U-87MG-AQP4-ECFP cells after complement and E5415A treatment. Log2-fold changes of E5415A + AC/IC with or without Eculizumab (30 µg/mL; 15 min)-treated cells were compared to untreated controls. GAPDH served as a housekeeping gene, and all ΔCt values of all genes were calculated before the normalization to untreated cells.

    Eculizumab purchased from MedChemExpress. Usage Cited in: Blood Vessel Thromb Hemost. 2025 Dec 22.

    Effect of complement inhibition and FcγRII blockade on patient serum-induced platelet aggregation in HIMEA. Platelet aggregation induced by patients’ serum obtained during active disease (T2Pre) in the presence of (UFH, 100 IU/mL) was reduced by treatment with the anti-C5 antibody Eculizumab (0.35 mg/mL; 20 min), the C3 inhibitor compstatin (0.12 and 0.18 mg/mL), or the FcγRII-blocking antibody IV.3 (35 μg/mL). Results are expressed as the percentage of residual platelet reactivity relative to aggregation observed with UFH 100 IU/mL alone.

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Eculizumab (Anti-Human C5, Humanized Antibody) is a long-acting humanized monoclonal antibody targeted against complement C5. Eculizumab inhibits the cleavage of C5 into C5a and C5b and inhibits deployment of the terminal complement system including the formation of membrane attack complex (MAC). Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in mice. Eculizumab can be used in hemolysis studies[1][2].

    Isotype

    Human IgG2 kappa
    Recommend Isotype Controls
    Species Reactivity

    Human
    IC50 & Target

    Complement C5
    In Vitro

    Eculizumab (3-100 μg/mL) completely prevents MAC deposition, terminal axonal neurofilament loss, and damage to perisynaptic Schwann cells, and inhibits the increase in MEPP frequency, asynchronous twitching of muscle fibres, and the occurrence of 'silent' NMJs, and prevents CGM3/NHS-induced loss of contraction force in a concentration-dependent manner in the in vitro MFS model[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Eculizumab Related Antibodies
    In Vivo

    Eculizumab (200 μg; i.v.; before intraperitoneal injection of NHS) completely prevents the development of weakness, respiratory difficulties, and almost completely prevents the occurrence of 'silent' NMJs, and preserves the normal contraction and NMJ function in the in vivo Miller Fisher syndrome (MFS) mouse model[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
    Clinical Trial
    Gene ID

    727  [NCBI]

    Accession
    Application

    ELISA, FACS, Functional assay
    Conjugated

    Unconjugated
    Reconsititution

    The product can be reconstituted/diluted with sterile PBS or saline.
    Molecular Weight

    145.74 kDa

    CAS No.
    Appearance

    Liquid

    Color

    Colorless to light yellow

    SMILES

    [Eculizumab]
    Shipping

    Shipping with dry ice.
    Formulation

    Please refer to the lot-specific COA for specific buffer information.
    Storage

    Please store the product under the recommended conditions in the Certificate of Analysis.
    Format
    • Human IgG2-IgG4 kappa
    Biological Activity
    • Flow cytometric analysis of 1X106 HepG2 cells with Eculizumab (HY-P9914, red). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then stained with the primary antibody at 1/50 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG2 kappa Isotype Control (HY-P99002, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
    • Immobilized Human Complement C5 Protein (Flag Tag) can bind Eculizumab. The EC50 for this effect is 3.17 ng/mL.
    Purity & Documentation

    Purity: 99.88%

    SDS (252 KB)

    COA (232 KB) SDS-PAGE (93 KB) SEC-HPLC (195 KB)

    Inhibitory Antibodies User Guide (603 KB)
    References
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Eculizumab Related Classifications

    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass   Concentration   Volume   Molecular Weight *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
    × = ×
    C1   V1   C2   V2
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Eculizumab219685-50-4Anti-Human C5, Humanized Antibody h5G1.1Complement Systemhumanized monoclonal antibodycomplement C5C5aC5bmembrane attack complexMAChaemolysisInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Eculizumab
    Cat. No.:
    HY-P9914
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (252 KB) Français - FR (252 KB) Deutsch - DE (252 KB) Norwegian - NO (252 KB) Español - ES (252 KB) Swedish - SV (252 KB) Italian - IT (252 KB) Korean - KR (252 KB) Portuguese - PT (252 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.